eNewsroom for: SomaGenics Inc.

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/SomaGenics Inc.//Screen shot 2011-09-20 at 8.29.16 AM.png

SomaGenics Inc. Company Profile

SomaGenics is a privately held company that develops innovative RNA technologies for therapeutic and diagnostic uses. SomaGenics' lead therapeutic program, against hepatitis C virus, has successfully completed efficacy evaluations in preclinical animal models and is ready for clinical development.

News from SomaGenics Inc.:

SomaGenics Secures $1.8M in Funding From NIH to Further Develop the Real-Seq® Technology Platform

SANTA CRUZ, Calif., Oct. 4, 2016 /PRNewswire/ — SomaGenics has been awarded a $1.8M two-year NIH SBIR Phase II grant to further develop its RealSeq®–AC technology for next-generation sequencing (NGS) of small RNAs such as microRNA. Real-Seq®-AC dramatically reduces bias in small RNA sequ…

Rubicon Genomics Licenses Commercialization Rights From SomaGenics for Its RealSeq®-AC Technology for High-Throughput Sequencing of Small RNA's

SANTA CRUZ, Calif., July 28, 2016 /PRNewswire/ — SomaGenics Inc. today announced that it has signed a licensing agreement with Rubicon Genomics, Inc. for commercialization of SomaGenics' RealSeq®-AC library preparation technology for sequencing small RNAs, including micro-RNAs…

Somagenics Awarded Second NIH Grant to Develop resQ-RNA™ Technology to Quantify Fragmented mRNA From Degraded Samples

SANTA CRUZ, Calif., Feb. 9, 2016 /PRNewswire/ — Somagenics has been awarded a second phase I SBIR grant from NIH to develop its resQ-RNATM technology for quantitative real-time PCR of fragmented RNA samples. Fragmentation of RNA is a particular problem in tissue samples that have been preserv…

SomaGenics Launches miR-ID® Platform and Assays for Highly Sensitive and Specific Quantification of microRNAs (miRNAs)

SANTA CRUZ, Calif., Oct. 7, 2015 /PRNewswire/ — SomaGenics, Inc. today announced the launch of its novel miR-ID® platform and assays for detecting miRNA using a circularization-based RT-qPCR method.  miR-ID® is highly sensitive, uses single-dye detection, and can discriminate mi…

SomaGenics Awarded 2-Year NIH Grant to Develop NGS microRNA Library Technology

SANTA CRUZ, Calif., April 28, 2015 /PRNewswire/ — SomaGenics has been awarded a two-year NIH grant to develop its novel RealSeq™–T technology for targeted next-generation sequencing (NGS) of small RNAs such as microRNA. There is increasing interest in using NGS for miRNA biomarker disc…

SomaGenics Receives $2,275,000 in NIH Funding to Develop its RNAi Therapeutics and microRNA Technologies

SANTA CRUZ, Calif., Dec. 18, 2014 /PRNewswire/ — SomaGenics has recently been awarded $2,275,000 in Small Business Innovation Research (SBIR) grants from the NIH to further develop and expand its RNA-based technologies in the areas of wound healing, hepatitis delta virus (HDV) therapeutic…

SomaGenics Awarded Four Patents Spanning Its miRNA and RNAi Programs

SANTA CRUZ, Calif., Dec. 16, 2014 /PRNewswire/ — SomaGenics, Inc. has had four patents covering various aspects of its small RNA platform technologies issued or allowed by the US and European Patent Offices. Two of these patents cover short hairpin RNA (shRNA) and small interfering RNA (siRNA…

SomaGenics Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation NIH Grants

SANTA CRUZ, Calif., Nov. 12, 2012 /PRNewswire/ — SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, has been awarded US Patent No. 8,283,460 for key aspects of the company's sshRNA therapeutic platform.  sshRNAs are small synthetic stem-loop (or ha…

SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform

SANTA CRUZ, Calif., July 24, 2012 — SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, announced the publication of a study reporting the mechanism of action of its sshRNAs, the class of molecules that forms the basis of the company's therapeutic platform…

SomaGenics’ sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus

SANTA CRUZ, Calif., Sept. 20, 2011 — SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, presented exciting data on the efficacy of RNA interference (RNAi) therapeutics against Hepatitis C virus (HCV) based on the company's sshRNA platform. SomaGenics,…